长效口服溴隐亭（帕罗西汀SRO）治疗高催乳素血症。

Long-acting oral bromocriptine (Parlodel SRO) in the treatment of hyperprolactinemia.

作者信息

Weingrill C O, Mussio W, Moraes C R, Portes E, Castro R C, Lengyel A M

机构信息

Department of Medicine, Escola Paulista de Medicina, Sao Paulo, Brazil.

出版信息

Fertil Steril. 1992 Feb;57(2):331-5. doi: 10.1016/s0015-0282(16)54840-7.

DOI:10.1016/s0015-0282(16)54840-7

PMID:1735484

Abstract

OBJECTIVES

To compare the effect of Parlodel SRO (Sandoz, Basel, Switzerland), a long-acting oral bromocriptine, to Parlodel (Sandoz) and to study the chronic effects of Parlodel SRO.

DESIGN

The study was twofold: (1) random, double-blind and (2) open.

SETTING

Patients were studied in an academic environment.

PATIENTS

Hyperprolactinemic patients were selected. Sixteen patients were treated during 1 month. Ten patients completed the 1-year follow-up.

INTERVENTIONS

Parlodel SRO or Parlodel was administered during 1 month (first 15 days: 5 mg/d; afterwards: 10 mg/d). Parlodel SRO was given during 1 year in variable doses (maximal 20 mg/d).

MAIN OUTCOME MEASURES

Prolactin (PRL) levels, clinical improvement, and side effects were evaluated.

RESULTS

After 1 month, 63% of the patients in both groups had normal PRL and 43% had menses. Side effects were similar. After 1 year all patients except one had normal PRL levels, and 89% were ovulating.

CONCLUSIONS

The efficacy, tolerability, and long duration of action of Parlodel SRO make it an excellent alternative for the treatment of hyperprolactinemic patients.

摘要